SCHEMBL5130992

SCHEMBL5130992

CCn1c(=O)[nH]c2sc(-c3cncnc3)c(C)c2c1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPC5 Q9UL62 1/20 0.37
QPCT Q16769 5/20 0.36
PDE4B Q07343 2/20 0.35
PDE7A Q13946 1/20 0.35
PDE4A P27815 1/20 0.35
ADORA2A P29274 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
ADORA2B P29275 2/20 0.33
CYP1A2 P05177 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
CDC7 O00311 1/20 0.32
ROCK2 O75116 1/20 0.32
MAP4K4 O95819 1/20 0.32
PIM1 P11309 1/20 0.32
GSK3B P49841 1/20 0.32
HIPK2 Q9H2X6 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32
ALDH1A1 P00352 2/20 0.32
LMNA P02545 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5129176 0.86 CYP2C19 (0.42) PDE4BPDE7AADORA2BCYP1A2ADORA3
SCHEMBL5132957 0.85 CDC7 (0.44) QPCTPDE4BPDE4AADORA2APDE4C
SCHEMBL5131718 0.82 ADORA2B (0.45) QPCTADORA2BCYP1A2ADORA3ALDH1A1
SCHEMBL5133333 0.79 KDM4E (0.42) ADORA2BCYP1A2ADORA3CDC7ROCK2
SCHEMBL5130829 0.79 ADORA2B (0.38) QPCTPDE4BPDE4AADORA2APDE4C
SCHEMBL5132706 0.78 PIK3CA (0.38)
SCHEMBL5132252 0.78 TMIGD3 (0.40) TRPC5PDE4BPDE4AADORA2APDE4C
SCHEMBL5130736 0.76 ADORA2B (0.56) ADORA2AADORA2BADORA3
SCHEMBL5132701 0.76 ADORA2A (0.36) QPCTPDE4BPDE4AADORA2APDE4C
SCHEMBL5130995 0.76 PDE4A (0.36) QPCTPDE4BPDE4AADORA2APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989210-A2 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2008-11-12 EP disclosed
WO-2007103776-A2 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2007-09-13 WO disclosed
US-20070208040-A1 e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction GILEAD PALO ALTO, INC. 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208040-A1 e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction CHRNE, CHRNA3, CHRNA1 TRPC5 2094/4885QPCT 2302/4885PDE4B 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.